Angiotensin Receptor Blockers and the Risk of Malignancy: A Note of Caution

ISSN： 0114-5916

Source： Drug Safety, Vol.33, Iss.9, 2010-09, pp. : 709-712

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug interactions with angiotensin receptor blockers

By Böhler Steffen Pittrow David Bramlage Peter Kirch Wilhelm

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 7-18

Informa Healthcare

Access to resources Recommend Favorite

Vascular benefits of angiotensin receptor blockers

By Voors Adriaan A

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-06 ,pp. : 987-997

Informa Healthcare

Access to resources Recommend Favorite

Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers)

By Coca Antonio

Clinical Drug Investigation, Vol. 28, Iss. 4, 2008-01 ,pp. : 211-220

Adis International

Access to resources Recommend Favorite

Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease

By Maggioni Aldo

Cardiovascular Drugs and Therapy, Vol. 20, Iss. 4, 2006-08 ,pp. : 295-308

Springer Publishing Company

Access to resources Recommend Favorite

Angiotensin receptor blockers and drug–drug interactions

By Sica Domenic A

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 139-140

Informa Healthcare

Access to resources Recommend Favorite